![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Drug-Drug Interactions of Ombitasvir/Paritaprevir/r plus Dasabuvir with Dolutegravir or Abacavir plus Lamivudine
|
|
|
Reported by Jules Levin
16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, May 26-28, 2015, Washington, DC, USA
Amit Khatri1, Roger Trinh2, Weihan Zhao3, Thomas Podsadecki2, Rajeev Menon1 1Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, United States; 2Infectious Disease, AbbVie, North Chicago, United States; 3Biometrics, AbbVie, North Chicago, United States
![Pharm1.gif](../images/060915/060815-14/Pharm1.gif)
![Pharm2.gif](../images/060915/060815-14/Pharm2.gif)
![Pharm3.gif](../images/060915/060815-14/Pharm3.gif)
![Pharm4.gif](../images/060915/060815-14/Pharm4.gif)
![Pharm5.gif](../images/060915/060815-14/Pharm5.gif)
![Pharm6.gif](../images/060915/060815-14/Pharm6.gif)
![Pharm7.gif](../images/060915/060815-14/Pharm7.gif)
![Pharm8.gif](../images/060915/060815-14/Pharm8.gif)
![Pharm9.gif](../images/060915/060815-14/Pharm9.gif)
![Pharm10.gif](../images/060915/060815-14/Pharm10.gif)
![Pharm11.gif](../images/060915/060815-14/Pharm11.gif)
![Pharm12.gif](../images/060915/060815-14/Pharm12.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|